ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback